Patent US4330558A successfully refreshed from Google Patents.
US4330558A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition and method for treating peripheral orthostatic hypotension
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1980-07-30
•
Granted: 1982-05-18
•
Expires: 2000-07-30
Abstract
Abstract A method for treating peripheral orthostatic hypotension which comprises administering DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof to a subject suffering from the disease. The composition may be administered either orally or parenterally.
Inventors
- 👤 Tomokazu Suzuki
- 👤 Akira Hayashi
- 👤 Yuichi Yamamura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 07:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61P; A61P25/00; A61P25/02; A61P9/00; A61P9/02
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
52 words
A method for treating peripheral orthostatic hypotension which comprises orally or parenterally administering DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof in an amount of from about 0.1 g to about 6 g per day to a human patient suffering from the disease until an intended result is obtained.
Claim 2
Independent Claim
52 words
A method for treating peripheral orthostatic hypotension which comprises orally or parenterally administering DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof in an amount of from about 0.1 g to about 6 g per day to a human patient suffering from the disease until an intended result is obtained.
Claim 3
Dependent Claim
23 words
A method for treating peripheral orthostatic hypotension according to claim 1, wherein DL-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof is administered.
Claim 4
Dependent Claim
23 words
A method for treating peripheral orthostatic hypotension according to claim 1, wherein L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof is administered.
References Cited (Backward Citations)
US3920728A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-17 | 1985-11-16 | 1986-05-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-17 | 1989-11-16 | 1990-05-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-17 | 1993-11-16 | 1994-05-18 | $7700.00 | Window Closed / Lapsed |